BackVistagen Therapeutics Overview

Vistagen Therapeutics Research & Development

Research & Development expenses for VTGN.

Quarterly R&D Expenses

$14.22M
↑ 25.81% YoY

As of Dec 31, 2025

Annual R&D Expenses (TTM)

$52.02M
↑ 42.12% YoY

Trailing 12 months ending Dec 31, 2025

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin